JP2003500360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500360A5 JP2003500360A5 JP2000619438A JP2000619438A JP2003500360A5 JP 2003500360 A5 JP2003500360 A5 JP 2003500360A5 JP 2000619438 A JP2000619438 A JP 2000619438A JP 2000619438 A JP2000619438 A JP 2000619438A JP 2003500360 A5 JP2003500360 A5 JP 2003500360A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- fap
- post
- reactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 206010025650 Malignant melanoma Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000001772 anti-angiogenic Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 201000008808 fibrosarcoma Diseases 0.000 description 2
- 230000003394 haemopoietic Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 108010050095 PT-100 dipeptide Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13586199P | 1999-05-25 | 1999-05-25 | |
| US60/135,861 | 1999-05-25 | ||
| PCT/US2000/014505 WO2000071135A1 (fr) | 1999-05-25 | 2000-05-25 | Agents anti-tumorales contenant des composes de boroproline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500360A JP2003500360A (ja) | 2003-01-07 |
| JP2003500360A5 true JP2003500360A5 (fr) | 2007-07-19 |
Family
ID=22470056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000619438A Pending JP2003500360A (ja) | 1999-05-25 | 2000-05-25 | ボロプロリン化合物類を含む抗癌剤 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1187619A1 (fr) |
| JP (1) | JP2003500360A (fr) |
| AU (1) | AU781897B2 (fr) |
| CA (1) | CA2373643A1 (fr) |
| HK (1) | HK1046846A1 (fr) |
| WO (1) | WO2000071135A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| CN1479622A (zh) | 2000-10-12 | 2004-03-03 | 联合使用阿普里汀和肌肉保护剂来治疗癌症 | |
| WO2003037373A1 (fr) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Utiilisation d'un antagoniste du recepteur ep2 ou ep4 et/ou d'un inhibiteur de la cox-1 pour traiter un cancer cervical |
| EP1469873A4 (fr) * | 2001-11-26 | 2007-10-03 | Tufts College | Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline |
| JP2003267966A (ja) * | 2002-03-13 | 2003-09-25 | Pola Chem Ind Inc | フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤 |
| EP1578434A2 (fr) * | 2002-07-09 | 2005-09-28 | Point Therapeutics, Inc. | Procedes et compositions ayant trait a des composes d'isoleucine boroproline |
| AU2004218883B2 (en) | 2003-03-12 | 2009-10-01 | Dana-Farber Cancer Institute, Inc. | Aplidine for multiple myeloma treatment |
| US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2146210A1 (fr) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY |
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| EP2556056A1 (fr) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
| KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료 |
| WO2012135570A1 (fr) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés |
| WO2012145361A1 (fr) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
| WO2012145603A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
| WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
| WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
| WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
| US9284337B2 (en) | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| US20200030411A1 (en) * | 2016-09-21 | 2020-01-30 | Agency For Science, Technology And Research | Methods and Compositions for Inhibiting Skin Inflammation and Determining Cancer Susceptibility |
| CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
| CN115779148B (zh) * | 2021-09-09 | 2024-02-23 | 中国科学院福建物质结构研究所 | 一种牙种植体表面涂层及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02268118A (ja) * | 1989-04-07 | 1990-11-01 | Mitsubishi Gas Chem Co Inc | 免疫賦活剤 |
| US5328936A (en) * | 1993-02-01 | 1994-07-12 | Rohm And Haas Company | Polymerization process for making porous polymeric particles |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5767242A (en) * | 1994-04-20 | 1998-06-16 | Boehringer Ingelheim Int'l Gmbh | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| US6100234A (en) * | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| PT1084129E (pt) * | 1998-06-05 | 2003-06-30 | Point Therapeutics Inc | Compostos de boroprolina ciclica |
| KR20010079669A (ko) * | 1998-08-21 | 2001-08-22 | 바바라 피. 월너 | 기질 활성의 조절 |
-
2000
- 2000-05-25 JP JP2000619438A patent/JP2003500360A/ja active Pending
- 2000-05-25 WO PCT/US2000/014505 patent/WO2000071135A1/fr active IP Right Grant
- 2000-05-25 CA CA002373643A patent/CA2373643A1/fr not_active Abandoned
- 2000-05-25 AU AU52927/00A patent/AU781897B2/en not_active Ceased
- 2000-05-25 EP EP00937801A patent/EP1187619A1/fr not_active Withdrawn
-
2002
- 2002-09-19 HK HK02106843.4A patent/HK1046846A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003500360A5 (fr) | ||
| CA2560058A1 (fr) | Procede inhibant la proliferation et accroissant l'apoptose de cellules cancereuses | |
| US20030023093A1 (en) | United states patent office | |
| AU2274201A (en) | Compounds and compositions for delivering active agents | |
| MY140398A (en) | 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES | |
| AU5873998A (en) | Quinazolinone compounds | |
| BG106003A (en) | New n-cyanomethylamides and compositions as protease inhibitors | |
| UA83738C2 (en) | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | |
| GB9404485D0 (en) | Benzamide analogues | |
| GEP20032973B (en) | 4-Amino Substituted-2-Substituted-1,2,3,4-Tetrahydroquinolines As CETP Inhibitors and Pharmaceutical Compositions Containing the Same | |
| AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| JP2008502694A (ja) | ボリン酸錯体の抗ウイルス使用 | |
| AU3492100A (en) | Oxadiazole compounds and compositions for delivering active agents | |
| AU4431200A (en) | 4'-c-ethynyl pyrimidine nucleosides | |
| JP2003532640A5 (fr) | ||
| NO20004162L (no) | Antitumor agens | |
| SE0203070D0 (en) | Novel compounds | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| Rahier et al. | Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons | |
| FR2699176B1 (fr) | Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant. | |
| Liu et al. | A study on the levels of calmodulin and DNA in human lung cancer cells | |
| WO2001041747A3 (fr) | Preparation pharmaceutique pour traiter des affections tumorales | |
| RU2005105693A (ru) | Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний | |
| CN102532020A (zh) | 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物 | |
| JP6542799B2 (ja) | 新規ｐｅｇ誘導体 |